Nasus Pharma (NSRX) Short term Debt (2024)
Nasus Pharma (NSRX) reported Short term Debt of $1.8 million for Q4 2024.
Nasus Pharma (NSRX) Short term Debt (2024) Analysis & Trends
Nasus Pharma has reported Short term Debt for 1 years, with the latest figure at $1.8 million in Q4 2024.
- For the quarter ending Q4 2024, Short term Debt changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2024 stood at $1.8 million (changed N/A YoY), and the FY2024 full-year result was $1.8 million, changed N/A from the prior year.
- Short term Debt for Q4 2024 stood at $1.8 million.
- The five-year high for Short term Debt was $1.8 million in Q4 2024, with the low at $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.80 Mn |